Dan Worthley


  • 2460 Citations
  • 28 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Research Focus: 
Our lab has focussed on cancer biology to bring clinical impact.
To this end we have developed a translational network of labs and clinics across Adelaide, Australia and the world to identify, develop, translate and then validate new approaches to preventing and treating gastrointestinal cancer, particularly colorectal and gastric cancer. Our laboratory is based at SAHMRI, but we collect tissues and perform human studies across every major metropolitan public hospital in South Australia as well as St Andrews private hospital. We have established two biotech companies, and collaborate with researchers from Columbia University, Oxford University, Melbourne University and University of Queensland.
Our major projects at the moment are:
1. Engineering probiotics to detect and prevent colorectal cancer.
2. Identifying new therapeutic targets in the colorectal cancer stroma.
3. Developing new prevention and treatment for patients with an inherited form of gastric cancer, GAPPS.
4. Studying human tumour organoids to better personalise therapy in cancer.

Education/Academic qualification

PhD, Doctor of Medicine , University of Queensland


MB BS (Honours), University of Adelaide

… → 1999

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Alpha-Blockers as colorectal cancer chemopreventive: Findings from a case-control study, human cell cultures, and in vivo preclinical testing

Suzuki, N., Niikura, R., Ihara, S., Hikiba, Y., Kinoshita, H., Higashishima, N., Hayakawa, Y., Yamada, A., Hirata, Y., Nakata, R., Okamoto, M., Sano, M., Kushiyama, A., Suzuki Ichinose, M., Woods, S., Worthley, D., Iwamoto, Y. & Koike, K., 1 Mar 2019, In : Cancer Prevention Research. 12, 3, p. 185-194 10 p.

Research output: Contribution to journalArticle

Cancer-associated fibroblasts—heroes or villains?

Gieniec, K. A., Butler, L., Worthley, D. & Woods, S. L., 13 Aug 2019, In : British Journal of Cancer. 121, 4, p. 293-302 10 p.

Research output: Contribution to journalReview article

10 Citations (Scopus)

Cancer-associated fibroblasts in gastrointestinal cancer

Kobayashi, H., Enomoto, A., Woods, S., Burt, A. D., Takahashi, M. & Worthley, D., 1 May 2019, In : Nature Reviews Gastroenterology and Hepatology. 16, 5, p. 282-295 14 p.

Research output: Contribution to journalReview article

20 Citations (Scopus)

Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis

Lannagan, T. R. M., Lee, Y. K., Wang, T., Roper, J., Bettington, M. L., Fennell, L., Vrbanac, L., Jonavicius, L., Somashekar, R., Gieniec, K., Yang, M., Ng, J. Q., Suzuki, N., Ichinose, M., Wright, J. A., Kobayashi, H., Putoczki, T. L., Hayakawa, Y., Leedham, S. J., Abud, H. E. & 10 othersYilmaz, Ö. H., Marker, J., Klebe, S., Wirapati, P., Mukherjee, S., Tejpar, S., Leggett, B. A., Whitehall, V. L. J., Worthley, D. L. & Woods, S. L., 1 Apr 2019, In : Gut. 68, 4, p. 684-692 9 p.

Research output: Contribution to journalArticle

13 Citations (Scopus)

Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis

Mizutani, Y., Kobayashi, H., Iida, T., Asai, N., Masamune, A., Hara, A., Esaki, N., Ushida, K., Mii, S., Shiraki, Y., Ando, K., Weng, L., Ishihara, S., Ponik, S. M., Conklin, M. W., Haga, H., Nagasaka, A., Miyata, T., Matsuyama, M., Kobayashi, T. & 11 othersFujii, T., Yamada, S., Yamaguchi, J., Wang, T., Woods, S., Worthley, D., Shimamura, T., Fujishiro, M., Hirooka, Y., Enomoto, A. & Takahashi, M., 15 Oct 2019, In : Cancer Research. 79, 20, p. 5367-5381 15 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)